Author:
Guo Yusheng,Chen Hebing,Wan Jiayu,Ren Yanqiao,Wu Feihong,Chen Lei,Sun Tao,Yang Lian,Zheng Chuansheng
Abstract
AbstractRecently, the efficacy of two low-invasive treatments, ablation, and radiotherapy, has been fully compared for the patients with the early-stage hepatocellular carcinoma (HCC). However, the comparison between radiotherapy plus ablation and ablation alone has been less frequently reported. Data from the Surveillance, Epidemiology, and End Results (SEER) database were searched for early-stage HCC patients treated with ablation plus radiotherapy or ablation alone. The outcome measures were overall survival (OS) and cancer-specific survival (CSS). The propensity score matching (PSM) was used to reduce selection bias. We included 240 and 6619 patients in the radiotherapy plus ablation group and ablation group before the PSM. After PSM, 240 pairs of patients were included. The median OS (mOS) and median CSS (mCSS) of patients receiving ablation alone were longer than that of receiving radiotherapy plus ablation (mOS: 47 vs. 34 months, P = 0.019; mCSS: 77 vs. 40 months, P = 0.018, after PSM) before and after PSM. The multivariate analysis indicated that radiotherapy plus ablation independent risk factor for OS and CSS before PSM, but the significance disappeared after PSM. The detailed subgroup analyses indicated ablation alone brought more benefit in very early-stage HCC and older patients. In addition, we found different types of radiotherapy might lead to different outcomes when combined with ablation. In conclusion, ablation alone is noninferior to radiotherapy plus ablation in patients with early-stage HCC. The additional radiation prior to ablation may bring survival benefits in the patients with higher tumor stage. However, due to the risk of selection bias in that study, the results should be interpreted cautiously.
Funder
National Nature Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1459–544.
2. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
3. Kreidieh, M., Zeidan, Y. H. & Shamseddine, A. The combination of stereotactic body radiation therapy and immunotherapy in primary liver tumors. J. Oncol. 2019, 4304817 (2019).
4. Kondo, Y., Kimura, O. & Shimosegawa, T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J. Gastroenterol. 21(1), 94–101 (2015).
5. Apisarnthanarax, S. et al. External beam radiation therapy for primary liver cancers: An ASTRO clinical practice guideline. Pract. Radiat. Oncol. 12(1), 28–51 (2022).